• Milestone Pharmaceuticals posted a net loss of $26.07 million for the quarter ended March 31, 2026, widening 25.6% year over year.
• Revenue turned positive with product sales of $238,000 following the U.S. retail pharmacy launch of CARDAMYST in January.
• Commercial expense climbed to $15.81 million, up 52.4%, while research and development spending fell to $3.25 million, down 34.7%.
• Interest expense rose to $4.14 million, up 342.3%, while interest income increased to $1.73 million, up 148.5%.
• Cash, cash equivalents, and short-term investments totaled $184.2 million at March 31, 2026; Phase 3 AFib-RVR program was initiated with first patient enrollment expected in second-half 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Milestone Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-059752), on May 13, 2026, and is solely responsible for the information contained therein.